JP2017533891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533891A5 JP2017533891A5 JP2017516489A JP2017516489A JP2017533891A5 JP 2017533891 A5 JP2017533891 A5 JP 2017533891A5 JP 2017516489 A JP2017516489 A JP 2017516489A JP 2017516489 A JP2017516489 A JP 2017516489A JP 2017533891 A5 JP2017533891 A5 JP 2017533891A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- seq
- amino acid
- acid sequence
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 45
- 102000004196 processed proteins & peptides Human genes 0.000 claims 45
- 108090000765 processed proteins & peptides Proteins 0.000 claims 45
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 35
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims 27
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 5
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 239000000833 heterodimer Substances 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000025316 Richter syndrome Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000004860 Blast Crisis Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 201000008736 Systemic mastocytosis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims 1
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462055695P | 2014-09-26 | 2014-09-26 | |
| US62/055,695 | 2014-09-26 | ||
| PCT/US2015/051314 WO2016048938A1 (en) | 2014-09-26 | 2015-09-22 | Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533891A JP2017533891A (ja) | 2017-11-16 |
| JP2017533891A5 true JP2017533891A5 (enExample) | 2018-11-01 |
| JP6839075B2 JP6839075B2 (ja) | 2021-03-03 |
Family
ID=55581876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516489A Active JP6839075B2 (ja) | 2014-09-26 | 2015-09-22 | Ｃｄ１９及びｃｄ３に結合できる二重特異性１価ダイアボディ並びにその使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US10633443B2 (enExample) |
| EP (1) | EP3197917B1 (enExample) |
| JP (1) | JP6839075B2 (enExample) |
| KR (1) | KR20170063755A (enExample) |
| CN (1) | CN107484416A (enExample) |
| AP (1) | AP2017009823A0 (enExample) |
| AR (1) | AR101997A1 (enExample) |
| AU (1) | AU2015321546B2 (enExample) |
| CA (1) | CA2962603A1 (enExample) |
| CL (1) | CL2017000711A1 (enExample) |
| CO (1) | CO2017002793A2 (enExample) |
| CR (1) | CR20170109A (enExample) |
| CU (1) | CU20170041A7 (enExample) |
| DO (1) | DOP2017000083A (enExample) |
| EA (1) | EA201790719A1 (enExample) |
| ES (1) | ES2935062T3 (enExample) |
| IL (1) | IL251377B (enExample) |
| MA (1) | MA40573A (enExample) |
| MD (1) | MD20170040A2 (enExample) |
| MX (1) | MX375669B (enExample) |
| NI (1) | NI201700037A (enExample) |
| PE (1) | PE20170894A1 (enExample) |
| PH (1) | PH12017500544A1 (enExample) |
| SG (1) | SG11201702310QA (enExample) |
| TN (1) | TN2017000106A1 (enExample) |
| TW (1) | TWI706960B (enExample) |
| UY (1) | UY36316A (enExample) |
| WO (1) | WO2016048938A1 (enExample) |
| ZA (1) | ZA201701985B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| EA201790719A1 (ru) * | 2014-09-26 | 2017-07-31 | Макродженикс, Инк. | Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения |
| US10717778B2 (en) * | 2014-09-29 | 2020-07-21 | Duke University | Bispecific molecules comprising an HIV-1 envelope targeting arm |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| EA201891178A1 (ru) | 2015-12-14 | 2019-01-31 | Макродженикс, Инк. | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения |
| HRP20221202T1 (hr) * | 2016-09-23 | 2022-12-09 | Regeneron Pharmaceuticals, Inc. | Anti-muc16 (mucin 16) antitijela |
| BR112019012354A2 (pt) | 2016-12-21 | 2019-11-26 | Teneobio, Inc. | anticorpos apenas de cadeia pesada anti-bcma |
| SG11201907753TA (en) | 2017-02-24 | 2019-09-27 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| CN110891971B (zh) | 2017-06-20 | 2024-01-12 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
| KR20250029294A (ko) * | 2017-09-22 | 2025-03-04 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 이중특이적 cd3/cd19 폴리펩티드 복합체 |
| EA202090812A1 (ru) | 2017-09-22 | 2020-08-07 | Уси Байолоджикс Аэлэнд Лимитед | Новые биспецифические полипептидные комплексы |
| JP2020535181A (ja) * | 2017-09-29 | 2020-12-03 | ヤンセン バイオテツク，インコーポレーテツド | 低用量抗体組成物を安定化する新規製剤 |
| CN109706163A (zh) * | 2017-10-26 | 2019-05-03 | 深圳新诺微环生物科技有限公司 | 微环dna表达连接人与动物靶细胞与效应细胞的桥接分子及其应用 |
| CN109957026A (zh) * | 2017-12-22 | 2019-07-02 | 成都恩沐生物科技有限公司 | 共价多特异性抗体 |
| WO2019160904A1 (en) | 2018-02-15 | 2019-08-22 | Macrogenics, Inc. | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
| SG11202011597RA (en) | 2018-07-20 | 2020-12-30 | Teneobio Inc | Heavy chain antibodies binding to cd19 |
| CN109402168A (zh) * | 2018-10-30 | 2019-03-01 | 深圳新诺微环生物科技有限公司 | 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用 |
| BR112021008486A2 (pt) * | 2018-11-01 | 2021-10-26 | Shandong New Time Pharmaceutical Co., Ltd | Anticorpo biespecífico e seu uso |
| AU2019339582A1 (en) * | 2018-12-04 | 2021-06-17 | Novartis Ag | Binding molecules against CD3 and uses thereof |
| AU2020270888A1 (en) * | 2019-04-08 | 2021-11-04 | Memorial Sloan Kettering Cancer Center | CD19 antibodies and methods of using the same |
| TWI905099B (zh) | 2019-05-21 | 2025-11-21 | 瑞士商諾華公司 | Cd19 結合分子及其用途 |
| CN116987197A (zh) * | 2019-06-20 | 2023-11-03 | 成都恩沐生物科技有限公司 | 共价多特异性抗体 |
| CA3170330A1 (en) | 2020-02-21 | 2021-08-26 | Macrogenics, Inc. | Cd137 binding molecules and uses thereof |
| SI4284512T1 (sl) | 2021-01-28 | 2025-06-30 | Regeneron Pharmaceuticals, Inc. | Sestavki in postopki za zdravljenje sindroma sproščanja citokinov |
| CN113488112A (zh) * | 2021-06-10 | 2021-10-08 | 五邑大学 | 一种共价结合预测方法及装置 |
| WO2023036326A1 (zh) * | 2021-09-13 | 2023-03-16 | 江苏先声药业有限公司 | 抗人cd3抗体及其应用 |
| US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| IL322545A (en) | 2023-02-17 | 2025-10-01 | Regeneron Pharma | Induced NK cells responding to bispecific CD3/TAA antibodies |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE37983T1 (de) | 1982-04-22 | 1988-11-15 | Ici Plc | Mittel mit verzoegerter freigabe. |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| AU6290090A (en) | 1989-08-29 | 1991-04-08 | University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
| WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| CA2071867A1 (en) | 1989-11-06 | 1991-05-07 | Edith Mathiowitz | Method for producing protein microspheres |
| CA2109528A1 (en) | 1991-05-01 | 1992-11-02 | Gregory A. Prince | A method for treating infectious respiratory diseases |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| CA2207961A1 (en) | 1995-01-05 | 1996-07-11 | Robert J. Levy | Surface-modified nanoparticles and method of making and using same |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| AU710347B2 (en) | 1995-08-31 | 1999-09-16 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| DK0885002T3 (da) | 1996-03-04 | 2011-08-22 | Penn State Res Found | Materialer og fremgangsmåder til forøgelse af cellulær internalisering |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| CA2277801C (en) | 1997-01-16 | 2002-10-15 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| CA2336139C (en) | 1998-06-24 | 2008-10-14 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| AU2001270609A1 (en) | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| US6992234B2 (en) | 2000-11-06 | 2006-01-31 | The Jackson Laboratory | FcRn-based therapeutics for the treatment of auto-immune disorders |
| ITRM20010408A1 (it) | 2001-07-10 | 2003-01-10 | Univ Napoli Federico Ii | Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2. |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| DE60124912T2 (de) | 2001-09-14 | 2007-06-14 | Affimed Therapeutics Ag | Multimerische, einzelkettige, Tandem-Fv-Antikörper |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US9284375B2 (en) * | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| EP3479844B1 (en) | 2005-04-15 | 2023-11-22 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| JP5090366B2 (ja) | 2005-12-16 | 2012-12-05 | アイビーシー ファーマスーティカルズ，インク． | 多価イムノグロブリン系生物活性アセンブリー |
| EP2418223A3 (en) | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| EP2059533B1 (en) | 2006-08-30 | 2012-11-14 | Genentech, Inc. | Multispecific antibodies |
| ES2702087T3 (es) | 2007-06-21 | 2019-02-27 | Macrogenics Inc | Diacuerpos covalentes y sus usos |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| WO2010028796A1 (en) | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Trispecific hexavalent antibodies |
| WO2010028797A1 (en) | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Multivalent antibodies |
| WO2010028795A1 (en) | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Multivalent antibodies |
| SG172254A1 (en) | 2008-12-19 | 2011-07-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
| NZ594665A (en) | 2009-03-20 | 2013-08-30 | Genentech Inc | Bispecific anti-her antibodies |
| EP2435473B1 (en) | 2009-05-27 | 2013-10-02 | F.Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| EP2525820B1 (en) * | 2010-01-19 | 2016-05-11 | Immunomedics, Inc. | Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r) |
| US20110206672A1 (en) * | 2010-02-25 | 2011-08-25 | Melvyn Little | Antigen-Binding Molecule And Uses Thereof |
| US9637557B2 (en) | 2010-04-23 | 2017-05-02 | Genentech, Inc. | Production of heteromultimeric proteins |
| CA2807127C (en) | 2010-08-02 | 2019-02-12 | Leslie S. Johnson | Covalent diabodies and uses thereof |
| US9750806B2 (en) | 2011-05-17 | 2017-09-05 | Trion Research Gmbh | Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties |
| CN107827985A (zh) * | 2011-05-21 | 2018-03-23 | 宏观基因有限公司 | 能够与人和非人cd3结合的cd3结合分子 |
| WO2012162068A2 (en) | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use for extending serum half-life |
| WO2012162583A1 (en) | 2011-05-26 | 2012-11-29 | Ibc Pharmaceuticals, Inc. | Design and construction of novel multivalent antibodies |
| WO2013003652A1 (en) | 2011-06-28 | 2013-01-03 | Sea Lane Biotechnologies, Llc | Multispecific stacked variable domain binding proteins |
| EP2729488A4 (en) | 2011-07-06 | 2015-01-14 | Medimmune Llc | PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES |
| PH12014500380A1 (en) * | 2011-08-17 | 2022-05-02 | Glaxo Group Ltd | Modified proteins and peptides |
| EP2812432B1 (en) | 2012-02-10 | 2020-10-14 | Research Corporation Technologies, Inc. | Fusion proteins comprising immunoglobulin constant domain-derived scaffolds |
| WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| KR20150013188A (ko) | 2012-05-24 | 2015-02-04 | 에프. 호프만-라 로슈 아게 | 다중특이적 항체 |
| US20140154253A1 (en) * | 2012-07-13 | 2014-06-05 | Zymeworks Inc. | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| WO2014106004A2 (en) | 2012-12-28 | 2014-07-03 | Abbvie, Inc. | High-throughput system and method for identifying antibodies having specific antigen binding activities |
| CN105051069B (zh) | 2013-01-14 | 2019-12-10 | Xencor股份有限公司 | 新型异二聚体蛋白 |
| PL3587448T3 (pl) * | 2013-03-15 | 2021-11-29 | Xencor, Inc. | Białka heterodimeryczne |
| US11384149B2 (en) * | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
| UA116479C2 (uk) * | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
| EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
| TWI742423B (zh) * | 2014-05-29 | 2021-10-11 | 美商宏觀基因股份有限公司 | 特異性結合多種癌症抗原的三特異性結合分子和其使用方法 |
| TWI693232B (zh) * | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| EA201790719A1 (ru) * | 2014-09-26 | 2017-07-31 | Макродженикс, Инк. | Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения |
| US10717778B2 (en) * | 2014-09-29 | 2020-07-21 | Duke University | Bispecific molecules comprising an HIV-1 envelope targeting arm |
| AU2015380455A1 (en) * | 2015-01-26 | 2017-08-03 | Macrogenics, Inc. | Multivalent molecules comprising DR5-binding domains |
| EP3337507A4 (en) * | 2015-08-17 | 2019-04-24 | MacroGenics, Inc. | BIS-SPECIFIC MONOVALENTS DIABODIES WITH ABILITY TO BIND B7-H3 AND CD3 AND USES THEREOF |
| TW201720458A (zh) * | 2015-12-04 | 2017-06-16 | 宏觀基因股份有限公司 | 能夠結合cd19 和cd3 的雙特異性單價雙抗體以及其用途 |
| US11596699B2 (en) * | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
| EP3464378A4 (en) * | 2016-06-07 | 2020-06-17 | MacroGenics, Inc. | METHOD FOR USE OF CD32B X CD79B BINDING MOLECULES IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS |
| SG11201907753TA (en) * | 2017-02-24 | 2019-09-27 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| WO2019118266A1 (en) * | 2017-12-12 | 2019-06-20 | Macrogenics Inc. | Bispecific cd 16-binding molecules and their use in the treatment of disease |
| WO2019160904A1 (en) * | 2018-02-15 | 2019-08-22 | Macrogenics, Inc. | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
| US20210246194A1 (en) * | 2018-05-18 | 2021-08-12 | Macrogenics, Inc. | Optimized gp41-Binding Molecules and Uses Thereof |
-
2015
- 2015-09-22 EA EA201790719A patent/EA201790719A1/ru unknown
- 2015-09-22 PE PE2017000512A patent/PE20170894A1/es not_active Application Discontinuation
- 2015-09-22 MA MA040573A patent/MA40573A/fr unknown
- 2015-09-22 AP AP2017009823A patent/AP2017009823A0/en unknown
- 2015-09-22 JP JP2017516489A patent/JP6839075B2/ja active Active
- 2015-09-22 ES ES15844698T patent/ES2935062T3/es active Active
- 2015-09-22 CR CR20170109A patent/CR20170109A/es unknown
- 2015-09-22 MD MDA20170040A patent/MD20170040A2/ro not_active Application Discontinuation
- 2015-09-22 TW TW104131330A patent/TWI706960B/zh active
- 2015-09-22 EP EP15844698.9A patent/EP3197917B1/en active Active
- 2015-09-22 CN CN201580051198.9A patent/CN107484416A/zh active Pending
- 2015-09-22 SG SG11201702310QA patent/SG11201702310QA/en unknown
- 2015-09-22 CA CA2962603A patent/CA2962603A1/en active Pending
- 2015-09-22 AR ARP150103050A patent/AR101997A1/es unknown
- 2015-09-22 US US15/514,334 patent/US10633443B2/en active Active
- 2015-09-22 MX MX2017003784A patent/MX375669B/es active IP Right Grant
- 2015-09-22 WO PCT/US2015/051314 patent/WO2016048938A1/en not_active Ceased
- 2015-09-22 AU AU2015321546A patent/AU2015321546B2/en active Active
- 2015-09-22 TN TN2017000106A patent/TN2017000106A1/en unknown
- 2015-09-22 UY UY0001036316A patent/UY36316A/es unknown
- 2015-09-22 CU CUP2017000041A patent/CU20170041A7/xx unknown
- 2015-09-22 KR KR1020177010716A patent/KR20170063755A/ko not_active Ceased
-
2017
- 2017-03-22 ZA ZA2017/01985A patent/ZA201701985B/en unknown
- 2017-03-23 PH PH12017500544A patent/PH12017500544A1/en unknown
- 2017-03-23 DO DO2017000083A patent/DOP2017000083A/es unknown
- 2017-03-24 CO CONC2017/0002793A patent/CO2017002793A2/es unknown
- 2017-03-24 NI NI201700037A patent/NI201700037A/es unknown
- 2017-03-24 CL CL2017000711A patent/CL2017000711A1/es unknown
- 2017-03-26 IL IL251377A patent/IL251377B/en active IP Right Grant
-
2020
- 2020-03-03 US US16/807,514 patent/US11639386B2/en active Active
-
2023
- 2023-03-20 US US18/186,353 patent/US20230399399A1/en not_active Abandoned
-
2025
- 2025-06-18 US US19/242,270 patent/US20250313628A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533891A5 (enExample) | ||
| JP2017504577A5 (enExample) | ||
| US20220324931A1 (en) | FUSION PROTEINS COMPRISING A BINDING PROTEIN AND AN INTERLEUKIN-15 POLYPEPTIDE HAVING A REDUCED AFFINITY FOR IL15Ra AND THERAPEUTIC USES THEREOF | |
| JP2024099850A5 (enExample) | ||
| FI3946621T3 (fi) | Mage a4 -t-solureptoreja | |
| NZ750366A (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| JP2016525551A5 (enExample) | ||
| HRP20220553T1 (hr) | Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela | |
| JP2016527314A5 (enExample) | ||
| JP2019531725A5 (enExample) | ||
| JP2018504143A5 (enExample) | ||
| JP2018503380A5 (enExample) | ||
| HRP20160422T1 (hr) | Protutijela protiv flt3 postupci njihove upotrebe | |
| JP2020501531A5 (enExample) | ||
| JP2019524693A5 (enExample) | ||
| JP2017537620A5 (enExample) | ||
| JP2010532169A5 (enExample) | ||
| NZ623319A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| JP2013527761A5 (enExample) | ||
| JP2019535306A5 (enExample) | ||
| JP2009539380A5 (enExample) | ||
| JP2010535032A5 (enExample) | ||
| CA2798390A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| JP2016527286A5 (enExample) | ||
| JP2018501208A5 (enExample) |